Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
5.63
-0.06 (-0.97%)
Nov 11, 2026, 4:08 PM HKT
HKG:3613 Revenue
Beijing Tong Ren Tang Chinese Medicine Company had revenue of 601.89M HKD in the half year ending June 30, 2026, a decrease of -9.43%. This brings the company's total for the last twelve months to 1.35B, down -20.79% year-over-year. In the year 2025, Beijing Tong Ren Tang Chinese Medicine Company had annual revenue of 1.51B, down -6.10%. That makes Beijing Tong Ren Tang Chinese Medicine Company the 18,561st largest company in the world by revenue and 1,081st in Hong Kong.
Revenue (ttm)
1.35B
Revenue Growth
-20.79%
P/S Ratio
3.49
Revenue / Employee
1.77M
Employees
763
Market Cap
4.71B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full HKG:3613 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.51B | -98.29M | -6.10% |
| Dec 31, 2024 | 1.61B | 86.70M | 5.69% |
| Dec 31, 2023 | 1.52B | -206.15M | -11.91% |
| Dec 31, 2022 | 1.73B | 174.94M | 11.24% |
| Dec 31, 2021 | 1.56B | 240.81M | 18.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
Revenue RankingsBeijing Tong Ren Tang Chinese Medicine Company News
- 2 months ago - Beijing Tong Ren Tang Chinese Medicine Company Earnings release: H1 2026 - Filings
- 2 months ago - Beijing Tong Ren Tang Chinese Medicine Company Quarterly report: H1 2026 - Filings
- 7 months ago - Beijing Tong Ren Tang Chinese Medicine Company Earnings release: H2 2025 - Filings
- 7 months ago - Beijing Tong Ren Tang Chinese Medicine Company Annual report: H2 2025 - Filings